Abstract | BACKGROUND: AIM: To investigate the efficacy of levocetirizine, 5 mg, and placebo for the symptoms and signs of CIU, as well as for the QoL and productivity. METHODS: The primary criteria of evaluation were the pruritus severity scores over 1 week of treatment and over 4 weeks. The QoL was assessed via the Dermatology Life Quality Index (DLQI). RESULTS: Baseline pruritus severity scores were comparable in the two treatment groups (2.06+/-0.58). After 1 week, levocetirizine was superior to placebo and demonstrated a considerable efficacy (difference=0.78, P<0.001). This efficacy was maintained over the entire study period (4 weeks, P<0.001). The number and size of wheals were considerably reduced compared with placebo over 1 week and over the total treatment period (P <or= 0.001). This was paralleled by an improvement in the QoL (DLQI: 7.3 units in the levocetirizine group and 2.4 units in the placebo group) and a higher productivity at work in the levocetirizine group (3.0 workdays lost per patient per month in the placebo group, 0.3 in the levocetirizine group). No unexpected adverse events occurred. CONCLUSIONS:
Levocetirizine, 5 mg once daily, is an effective treatment for CIU, characterized not only by a rapid and sustained response, but also by an important improvement in QoL.
|
Authors | Alexander Kapp, Werner J Pichler |
Journal | International journal of dermatology
(Int J Dermatol)
Vol. 45
Issue 4
Pg. 469-74
(Apr 2006)
ISSN: 0011-9059 [Print] England |
PMID | 16650180
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Histamine H1 Antagonists, Non-Sedating
- Piperazines
- levocetirizine
- Cetirizine
|
Topics |
- Adult
- Cetirizine
(therapeutic use)
- Chronic Disease
- Double-Blind Method
- Efficiency
- Female
- Germany
- Histamine H1 Antagonists, Non-Sedating
(therapeutic use)
- Humans
- Male
- Piperazines
(therapeutic use)
- Quality of Life
- Severity of Illness Index
- Sick Leave
(statistics & numerical data)
- Switzerland
- Urticaria
(drug therapy, psychology)
|